Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Romanian blood donors screening: is it really necessary and/or mandatory?

Hâţu G, Brumboiu MI, Gorgan IN, Bocşan IS.

Rev Med Chir Soc Med Nat Iasi. 2013 Jul-Sep;117(3):741-6.

PMID:
24502043
2.

[Safe blood in the absence of viral infections due to HBV, HCV and HIV in serological window period in donors].

Contreras AM, Reta CB, Torres O, Celis A, Domínguez J.

Salud Publica Mex. 2011;53 Suppl 1:S13-8. Spanish.

4.

Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.

Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ; German Red Cross NAT Study Group.

Transfusion. 2008 Aug;48(8):1558-66. doi: 10.1111/j.1537-2995.2008.01718.x. Epub 2008 May 6.

PMID:
18466173
5.

[Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (Nucleic Acid Testing)].

Pillonel J, Laperche S; Groupe "Agents Transmissibles par Transfusion" de la Société française de transfusion sanguine; Etablissement français du sang; Centre de transfusion sanguine des armées.

Transfus Clin Biol. 2004 Apr;11(2):81-6. French.

PMID:
15120104
6.

Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT.

Seed CR, Cheng A, Ismay SL, Bolton WV, Kiely P, Cobain TJ, Keller AJ; Virology Subcommittee of the National Donor and Product Safety Committee, Australian Red Cross Blood Service.

Transfusion. 2002 Oct;42(10):1365-72.

PMID:
12423522
7.

Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000.

Chiavetta JA, Escobar M, Newman A, He Y, Driezen P, Deeks S, Hone DE, O'Brien SF, Sher G.

CMAJ. 2003 Oct 14;169(8):767-73.

8.

Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.

Velati C, Romanò L, Fomiatti L, Baruffi L, Zanetti AR; SIMTI Research Group.

Transfusion. 2008 Oct;48(10):2205-13. doi: 10.1111/j.1537-2995.2008.01813.x. Epub 2008 Jul 8.

PMID:
18631163
10.

Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus -1 & hepatitis B & C viruses in Indian blood donors.

Makroo RN, Choudhury N, Jagannathan L, Parihar-Malhotra M, Raina V, Chaudhary RK, Marwaha N, Bhatia NK, Ganguly AK.

Indian J Med Res. 2008 Feb;127(2):140-7.

PMID:
18403791
11.
12.

Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services.

O'Brien SF, Yi QL, Fan W, Scalia V, Kleinman SH, Vamvakas EC.

Transfusion. 2007 Feb;47(2):316-25.

PMID:
17302779
13.

Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: impact of individual-donation nucleic acid testing, 2004 through 2009.

Al Shaer L, AbdulRahman M, John TJ, AlHashimi A.

Transfusion. 2012 Nov;52(11):2300-9. doi: 10.1111/j.1537-2995.2012.03740.x. Epub 2012 Jun 13.

PMID:
22691239
14.

Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS)

Glynn SA, Kleinman SH, Schreiber GB, Busch MP, Wright DJ, Smith JW, Nass CC, Williams AE.

JAMA. 2000 Jul 12;284(2):229-35.

PMID:
10889598
15.
16.

Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT.

Weusten JJ, van Drimmelen HA, Lelie PN.

Transfusion. 2002 May;42(5):537-48.

PMID:
12084161
17.

Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.

Vermeulen M, Lelie N, Sykes W, Crookes R, Swanevelder J, Gaggia L, Le Roux M, Kuun E, Gulube S, Reddy R.

Transfusion. 2009 Jun;49(6):1115-25. doi: 10.1111/j.1537-2995.2009.02110.x. Epub 2009 Feb 27.

PMID:
19309474
18.

Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy.

Gonzalez M, Règine V, Piccinini V, Vulcano F, Giampaolo A, Hassan HJ.

Transfusion. 2005 Oct;45(10):1670-5.

PMID:
16181219
19.
20.

Incidence of viral markers and evaluation of the estimated risk in the Swiss blood donor population from 1996 to 2003.

Niederhauser C, Schneider P, Fopp M, Ruefer A, Lévy G.

Euro Surveill. 2005 Feb;10(2):14-6.

PMID:
15735314

Supplemental Content

Support Center